Semaglutide + Cagrilintide (Sema+Cagri) 2 mg + 2 mg PEN

One-Peptides SEMA+CAGRI 2 mg+2 mg PEN – semaglutide and cagrilintide blend in a pre-dissolved pen

Sema+Cagri 2 mg+2 mg PEN is a Research Use Only reagent blend containing two peptide components in one pre-dissolved pen: semaglutide and cagrilintide. The product is designed for laboratory research contexts where a fixed 1:1 peptide ratio is useful for studying GLP-1 and amylin/calcitonin-axis interaction.

This product is not CagriSema, not a medicine, not a dietary supplement and not intended for human or animal use. CagriSema is a Novo Nordisk clinical-development program involving semaglutide and cagrilintide in defined investigational protocols. One-Peptides Sema+Cagri PEN is a separate RUO reagent supplied for laboratory work only.

What is the Sema+Cagri blend – two peptides in one pen

• Semaglutide – 2 mg, a GLP-1 analog.
• Cagrilintide – 2 mg, a long-acting amylin/calcitonin analog.
• Total content: 4 mg of peptides in one pen, fixed 1:1 ratio.

The blend is intended to model combined incretin and amylin-related signaling. For the GLP-1 side of the mechanism, see the One Peptides article on semaglutide and the broader guide to GLP-1 peptides in metabolic research.

Semaglutide – GLP-1 analog

Semaglutide is a long-acting analog of glucagon-like peptide-1. It activates the GLP-1 receptor, which is involved in glucose-dependent insulin secretion, postprandial glucagon suppression, delayed gastric emptying and central satiety signaling. In clinical medicine, semaglutide is used in registered products such as Ozempic, Wegovy and Rybelsus, but this reagent blend is not a pharmaceutical product.

In research, semaglutide is often used as a mono-agonist comparator against dual and tri-agonist approaches, including tirzepatide and retatrutide. The broader incretin context is explained in the article about GLP-1, GIP and glucagon.

Cagrilintide – long-acting amylin/calcitonin analog

Cagrilintide is a long-acting analog related to the amylin/calcitonin receptor family. Amylin is co-secreted with insulin by pancreatic beta cells and contributes to satiety signaling, delayed gastric emptying and postprandial metabolic regulation. Cagrilintide has been studied as a peptide partner for semaglutide in weight-management research programs.

Mechanistically, the interest in the semaglutide+cagrilintide pairing comes from targeting two complementary axes: GLP-1 receptor signaling and amylin/calcitonin-receptor signaling. The blend therefore differs from GLP-1-only products such as Sema G PEN 2 mg, from dual incretin products such as GLP-1+GIP PEN, and from tri-agonist products such as Triple G PEN.

Sema+Cagri blend characteristics

Mechanism of synergy – what the literature suggests

The semaglutide+cagrilintide concept is based on combining two appetite and metabolic-regulation pathways. Semaglutide acts through GLP-1R, while cagrilintide acts through amylin/calcitonin-related receptor pathways. In clinical research, cagrilintide has been tested alone and in combination with semaglutide, with a focus on body-weight and appetite-regulation endpoints.

The mechanistic logic is different from incretin-only escalation. GLP-1+GIP PEN explores dual incretin signaling; Triple G PEN explores GLP-1/GIP/glucagon tri-agonism. Sema+Cagri combines GLP-1 signaling with amylin-family signaling, which makes it a distinct research model.

For comparison with advanced GLP-1/GIP/glucagon research, see the article on semaglutide versus retatrutide mechanisms and outcomes.

The informal shorthand used for retatrutide in online searches is explained in a separate entry: a glossary explanation of “reta”.

Sema+Cagri PEN RUO vs clinical CagriSema vs registered medicines

Applications in scientific research

• Combination-mechanism studies – comparison of GLP-1R signaling with amylin/calcitonin-receptor signaling in appetite and metabolic models.
• Cellular signaling assays – receptor-activity profiling, cAMP readouts, beta-arrestin reporters and pathway-selectivity analysis.
• Animal-model studies – obesity and insulin-resistance models with endpoints such as food intake, body weight, body composition, glucose tolerance and lipid parameters.
• Comparative peptide pharmacology – head-to-head experimental designs involving semaglutide-only, GLP-1+GIP, tri-agonist and semaglutide+cagrilintide models.
• Formulation and stability studies – work with fixed-ratio pre-dissolved blends, cold-chain handling and batch-to-batch analytical verification.

One Peptides quality specification

• HPLC >=98% for each peptide – two separate peaks in appropriate retention windows.
• MS confirmation – identity confirmation for both peptides, approximately 4113 Da for semaglutide and about 4500 Da for cagrilintide.
• COA per batch – batch-specific certificate with separate results for both peptides, synthesis date and lot number.
• Cold chain 2-8 °C – refrigerated logistics with monitoring.
• Batch traceability – lot number in three places: pen label, invoice and COA.

More information about quality-control workflow and certificates is available on the quality testing and certificates page.

Working with a pre-dissolved PEN in a laboratory protocol

The pre-dissolved pen format removes the first reconstitution step, which can reduce error in solvent-volume selection. However, it also fixes the initial concentration and peptide ratio, so experimental design must account for a constant 1:1 semaglutide:cagrilintide blend.

For general peptide-handling background, see the guide on how to dissolve peptides, the overview of bacteriostatic water and the peptide calculator. Even when reconstitution is not required, sterile handling, refrigeration and minimizing temperature cycling remain important.

Regulatory status and WADA

Sema+Cagri PEN is a Research Use Only reagent. It is not an EMA- or FDA-approved medicine, not a dietary supplement and not intended for use in humans or animals. It should not be confused with the Novo Nordisk CagriSema clinical-development program.

Semaglutide medicines are prescription-only therapeutic products. Cagrilintide combinations remain investigational in clinical programs. WADA status can change, and compounds affecting appetite, weight management or metabolic regulation should always be checked against the current WADA-AMA list. This product is not intended for athletes or performance enhancement.

FAQ – Frequently Asked Questions

References

1. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1).
2. Lau J et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
3. Frias JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).
4. Marso SP et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
5. Enebo LB et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.
6. Lau DCW et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.